S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

ORIC Oric Pharmaceuticals Inc

7.64

0.00 (0.00%)

Pre Market

Last Updated: 03:39:47

Delayed by 15 minutes

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Oric Pharmaceuticals (NASDAQ:ORIC)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Oric Pharmaceuticals Charts.

Oric Pharmaceuticals (NASDAQ:ORIC)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Oric Pharmaceuticals Charts.

Oric Pharmaceuticals Inc News

Form 8-K - Current report
Tuesday 25 February 2025 (7 days ago) • Edgar (US Regulatory)

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
Tuesday 25 February 2025 (7 days ago) • GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Tuesday 18 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 18 February 2025 (2 weeks ago) • Edgar (US Regulatory)

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
Tuesday 18 February 2025 (2 weeks ago) • GlobeNewswire Inc.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Friday 7 February 2025 (4 weeks ago) • GlobeNewswire Inc.

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
Monday 27 January 2025 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 13 January 2025 (2 months ago) • Edgar (US Regulatory)

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
Monday 13 January 2025 (2 months ago) • GlobeNewswire Inc.

ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
Monday 13 January 2025 (2 months ago) • GlobeNewswire Inc.

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Monday 6 January 2025 (2 months ago) • GlobeNewswire Inc.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Friday 3 January 2025 (2 months ago) • GlobeNewswire Inc.

More Oric Pharmaceuticals Inc News Articles

Valiant Eagle (PK)

Anavex Life Sciences

Asia Broadband (PK)

Rennova Health (CE)

Elite Pharmaceuticals (QB)

Bioelectronics (PK)

Global Developments (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions